You are here
P&T August 2012
By the end of 2012, states must figure out how they will provide exchanges for citizens to buy health care insurance. Much work remains to be done, including removing information barriers, to make health care accessible to all citizens by 2014.
Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.
Men with benign prostatic hyperplasia who received 5-ARIs and persisted with therapy had significantly reduced risks of acute urinary retention, less need for prostate surgery, and lower medical costs.
FDA approvals, drug indications, and updates